Integrated BioPharma, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Riva Sheppard
- Full Time Employees
- 153
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Building 15 Hillside NJ United States of America 07205
- IPO Date
- Oct 30, 1996
- CIK
- 0001016504
- Website
- ir.ibiopharma.com
- Similar Companies
- Business
- Integrated BioPharma, Inc. Integrated BioPharma, Inc. (OTCQX:INBP) manufactures, distributes, markets and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two main segments: Contract Manufacturing, which produces vitamins and nutritional supplements for distributors, multilevel marketers, and specialized health-care providers; and Other Nutraceutical Businesses, which distributes branded products such as Peaceful Sleep and Wheatgrass through mass market, grocery, drug, and vitamin retailers, sells private label vitamins and supplements via the internet, provides warehousing and fulfillment services, and distributes fine natural botanicals including multi-minerals and raw materials for DSM Nutritional Products LLC. Integrated BioPharma, Inc. conducts its operations through subsidiaries including Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc., and MDC Warehousing and Distribution, Inc., doing business as Chem International Inc.; it serves the nutraceutical industry with high-quality, U.S.-manufactured products from its headquarters in Hillside, New Jersey, with a sales office in Florida. Founded in 1980 and formerly known as Integrated Health Technologies, Inc., the company maintains approximately 153 employees and focuses on compliance with industry standards in the consumer staples sector, specifically packaged foods and personal care products. Recent financial reporting includes results for the quarter and fiscal year ended June 30, 2025, reflecting ongoing operations in manufacturing and distribution without noted major acquisitions, partnerships, funding rounds, or strategic shifts in the past one to two years.
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026
Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025
Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions
Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024
Integrated BioPharma Reports Results for Its Quarter and Fiscal Year Ended June 30, 2024
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2024
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2023
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2023
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2023
OTC Markets Group Welcomes Integrated BioPharma, Inc. to OTCQX
Integrated BioPharma: Strong Growth For Less Than A 5 P/E